Benign Prostatic Hyperplasia Market to Witness Growth by 2032 | Nymox Pharmaceutical, ASKA Pharmaceutical, Otsuka Pharmaceutical, Aiviva BioPharma, KAEL-GemVax, Dong-A ST/Mezzion

DelveInsight's "Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Benign Prostatic Hyperplasia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Benign Prostatic Hyperplasia market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Benign Prostatic Hyperplasia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Benign Prostatic Hyperplasia market.

Request for a Free Sample Report @ https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent Advancements in the Benign Prostatic Hyperplasia Market:

September 2023: Dongkook Pharmaceuticals has disclosed the initiation of phase 3 clinical trials examining DKF-313 alongside Dutasteride. This extensive study, spanning 48 weeks, employs a multi-center, randomized, double-blinded, parallel group approach to assess the efficacy and safety of DKF-313, a combination of dutasteride and tadalafil, among patients grappling with benign prostatic hyperplasia (BPH). The objective is to ascertain whether a once-daily regimen of DKF-313 for 48 weeks surpasses the efficacy of dutasteride (0.5 mg once daily) and tadalafil (5 mg once daily) independently, specifically in ameliorating BPH-LUTS, measured through alterations in IPSS total scores.
October 2023: Boston Scientific Corporation has announced a pivotal study encompassing clinical trial phases to explore the efficacy of alpha blocker and 5-alpha reductase inhibitor treatments. The study's primary goal is to compare the efficacy of water vapor thermotherapy using the REZŪM™ System against dual drug therapy in managing symptomatic benign prostatic hyperplasia (BPH) that remains unresponsive to alpha-blocker monotherapy, specifically in sexually active men.
October 2023: Elpen Pharmaceuticals has initiated a comprehensive study involving phases and clinical trials focusing on patients with Benign Prostate Hyperplasia (BPH). This investigation aims to examine the advantages of combination therapy (dutasteride-tamsulosin) versus monotherapy in terms of symptom improvement and long-term outcomes, such as acute urinary retention (AUR) and surgery, among men experiencing moderate to severe BPH. The primary endpoint after two years from the study's onset is the alteration in the IPSS score, while the primary endpoint after four years of treatment includes the duration until long-term outcomes manifest (such as AUR or surgical intervention) as well as the percentage of participants experiencing these outcomes. The study enrolled 4838 men aged at least 50 years with a prostate tumor size of ≥30 cm3 and a PSA level of ≥1.5 ng/mL.

Benign Prostatic Hyperplasia: An Overview

Benign Prostatic Hyperplasia (BPH) refers to a non-cancerous enlargement of the prostate gland. The prostate is a small gland situated beneath the bladder and around the urethra in males. It's responsible for producing fluid that nourishes and transports sperm.
As men age, the prostate gland commonly enlarges, leading to BPH. The exact cause of this enlargement is not entirely understood, but it's believed to be associated with hormonal changes related to aging, especially changes in the balance of sex hormones.
Symptoms of BPH can include:
Frequent or urgent need to urinate.
Difficulty starting urination.
Weak urine stream or a stream that stops and starts.
Increased frequency of urination at night (nocturia).
Inability to completely empty the bladder.
Complications from BPH can include urinary tract infections, bladder stones, urinary retention, kidney damage, and in severe cases, it can lead to bladder damage.
Treatment options for BPH vary depending on the severity of symptoms and the individual's health. Some common treatments include:
Watchful waiting: For mild symptoms, monitoring without immediate treatment might be suggested.
Medications: Alpha-blockers or 5-alpha-reductase inhibitors can help relax the prostate or reduce its size.
Minimally invasive therapies: Procedures like transurethral microwave therapy (TUMT), transurethral needle ablation (TUNA), or laser therapy can help reduce symptoms.
Surgery: In severe cases, surgical options like transurethral resection of the prostate (TURP), prostate laser surgery, or open prostatectomy might be recommended to remove part or all of the enlarged prostate.

Learn more about Benign Prostatic Hyperplasia, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Benign Prostatic Hyperplasia Market

The Benign Prostatic Hyperplasia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Benign Prostatic Hyperplasia market trends by analyzing the impact of current Benign Prostatic Hyperplasia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Benign Prostatic Hyperplasia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Benign Prostatic Hyperplasia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Benign Prostatic Hyperplasia market in 7MM is expected to witness a major change in the study period 2019-2032.

Request a sample and discover more about the report offerings at:
https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Benign Prostatic Hyperplasia Epidemiology

The Benign Prostatic Hyperplasia epidemiology section provides insights into the historical and current Benign Prostatic Hyperplasia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Benign Prostatic Hyperplasia market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Benign Prostatic Hyperplasia Epidemiology at: https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Benign Prostatic Hyperplasia Drugs Uptake

This section focuses on the uptake rate of the potential Benign Prostatic Hyperplasia drugs recently launched in the Benign Prostatic Hyperplasia market or expected to be launched in 2019-2032. The analysis covers the Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Benign Prostatic Hyperplasia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Benign Prostatic Hyperplasia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Benign Prostatic Hyperplasia Pipeline Development Activities

The Benign Prostatic Hyperplasia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Benign Prostatic Hyperplasia key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Benign Prostatic Hyperplasia pipeline development activities at: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Benign Prostatic Hyperplasia Therapeutics Assessment

Major key companies such as Nymox Pharmaceutical, ASKA Pharmaceutical, Otsuka Pharmaceutical, Aiviva BioPharma, KAEL-GemVax, Dong-A ST/Mezzion, and others are working proactively in the Benign Prostatic Hyperplasia Therapeutics market to develop novel therapies which will drive the Benign Prostatic Hyperplasia treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Benign Prostatic Hyperplasia Report Key Insights

1. Benign Prostatic Hyperplasia Patient Population
2. Benign Prostatic Hyperplasia Market Size and Trends
3. Key Cross Competition in the Benign Prostatic Hyperplasia Market
4. Benign Prostatic Hyperplasia Market Dynamics (Key Drivers and Barriers)
5. Benign Prostatic Hyperplasia Market Opportunities
6. Benign Prostatic Hyperplasia Therapeutic Approaches
7. Benign Prostatic Hyperplasia Pipeline Analysis
8. Benign Prostatic Hyperplasia Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Benign Prostatic Hyperplasia Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Benign Prostatic Hyperplasia Competitive Intelligence Analysis
4. Benign Prostatic Hyperplasia Market Overview at a Glance
5. Benign Prostatic Hyperplasia Disease Background and Overview
6. Benign Prostatic Hyperplasia Patient Journey
7. Benign Prostatic Hyperplasia Epidemiology and Patient Population
8. Benign Prostatic Hyperplasia Treatment Algorithm, Current Treatment, and Medical Practices
9. Benign Prostatic Hyperplasia Unmet Needs
10. Key Endpoints of Benign Prostatic Hyperplasia Treatment
11. Benign Prostatic Hyperplasia Marketed Products
12. Benign Prostatic Hyperplasia Emerging Therapies
13. Benign Prostatic Hyperplasia Seven Major Market Analysis
14. Attribute Analysis
15. Benign Prostatic Hyperplasia Market Outlook (7 major markets)
16. Benign Prostatic Hyperplasia Access and Reimbursement Overview
17. KOL Views on the Benign Prostatic Hyperplasia Market
18. Benign Prostatic Hyperplasia Market Drivers
19. Benign Prostatic Hyperplasia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Benign Prostatic Hyperplasia Market report here: https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Us:

Kritika Rehani
info@delveinsight.com
+91-9650213330
www.delveinsight.com

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.